Evidence map›Paper›PMID 42668284›Full record

ArticleEMBO molecular medicine2026

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.

Lijie Liu, Mengrong Yan, Ruoxu Liang, Qingxin Wu, Changbin Qu, Huiqi Wu, Zhi Liao, Huiyu Chen, Jingjing Zou, Zeyun Sun and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lijie Liu *State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.ORCID http://orcid.org/0009-0002-0544-8595
Mengrong Yan *Guangzhou National Laboratory, Guangzhou, China.ORCID http://orcid.org/0000-0003-0093-2775
Ruoxu Liang *State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Qingxin Wu *State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Changbin Qu *Guangzhou National Laboratory, Guangzhou, China.
Huiqi WuGuangzhou National Laboratory, Guangzhou, China.ORCID http://orcid.org/0009-0001-1120-0716
Zhi LiaoGuangzhou National Laboratory, Guangzhou, China.
Huiyu ChenState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jingjing ZouGuangzhou National Laboratory, Guangzhou, China.ORCID http://orcid.org/0009-0005-9682-2328
Zeyun SunGuangzhou National Laboratory, Guangzhou, China.
Dongyu NiuGuangzhou National Laboratory, Guangzhou, China.
Liyuan WuGuangzhou National Laboratory, Guangzhou, China.
Li ZhaoState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jialing DaiGuangzhou National Laboratory, Guangzhou, China.
Jialun ShenGuangzhou National Laboratory, Guangzhou, China.ORCID http://orcid.org/0000-0003-1371-0493
Long ZhangState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. zhang_long@gzlab.ac.cn.ORCID http://orcid.org/0009-0008-2255-1563
Wei ZhangState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. zhang_wei2@gzlab.ac.cn.ORCID http://orcid.org/0000-0001-8693-6747
Wei PengState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. peng_wei@gzlab.ac.cn.

Funding

Bureau of Science and Information Technology of Guangzhou Municipality | Guangzhou Municipal Science and Technology Program key projects (Guangzhou Science and Technology Program key projects) 2023QN10Y428GDSTC | Basic and Applied Basic Research Foundation of Guangdong Province ( ) 2025A1515011053Guangzhou National Laboratory GZNL2023A01007Guangzhou National Laboratory GZNL2025C01020Guangzhou National Laboratory YW-JCZD0105MOST | National Natural Science Foundation of China (NSFC) 32100142State Key Laboratory of Medicinal Chemical Biology (SKLMCB) 2025010State Key Laboratory of Medicinal Chemical Biology (SKLMCB) 2025013State Key Laboratory of Respiratory Disease (SKLRD) SKLRD-Z-202512
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, and stabilization of the prefusion (preF) conformation of the F glycoprotein is central for vaccine development. Here, we report a structure-guided engineering strategy that enhances preF stability by reducing the hydrophobic cavity within the trimeric F protein. Targeted modifications at metastability-associated sites generated RVF-88, a disulfide-free stabilized preF immunogen that preserves key neutralizing epitopes, including antigenic site Ø, while exhibiting improved structural integrity and long-term storage stability. Formulated as an unadjuvanted bivalent vaccine, RVF-88 elicited potent neutralizing antibody responses and durable immune protection lasting up to 5 months in mice. Vaccination also protected both mice and cotton rats against RSV challenge. Structural analyses confirmed the intended cavity-reduction design, revealing a reduced apical hydrophobic cavity volume and surface area while maintaining the prefusion architecture. Together, these findings establish hydrophobic cavity reduction as a rational strategy for stabilizing prefusion RSV F and provide a promising next-generation vaccine candidate with improved stability and immunogenicity for further clinical development.

Identifiers

PMID42668284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.